polyarticular juvenile idiopathic arthritis
Rheumatology · 2010–2019
No submission for this condition has carried consumer input, including the one made since the comments facility came into use.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| tocilizumab Treatment of severe active polyarticular juvenile idiopathic arthritis (JIA). | Mar 2019 | Recommended with restriction | none received |
| tocilizumab Treatment of active polyarticular course juvenile idiopathic arthritis (JIA) as a single-agent or in combination with methotrexate in patients under 18 years… | Nov 2013 | Recommended with restriction | no section in document |
| adalimumab Treatment of severe active polyarticular course juvenile idiopathic arthritis in patients aged 4 years and older, either in combination with methotrexate or as… | Mar 2010 | Recommended with restriction | no section in document |
What the PBS pays
$312M in government benefit over 2024–25, across 503,319 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| adalimumab | $241.9M |
| tocilizumab | $69.8M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.